






7-13-04

IFW

EXPRESS MAIL CERTIFICATE OF MAILING (37 CFR 1.10) Express Mail No.: EV332072599US		Docket No. 57294-019				
Applicant(s): Roger K. Cady						
Serial No. 10/808,008	Filing Date 03/24/2004	Examiner TBA	Group Art 1614			
Title: Method and Article for Treatment of Sensory Neuron Related Disorders Through Transdermal Application of Botulinum Toxin						
<p style="text-align: center;"><u>TO THE COMMISSIONER OF PATENTS AND TRADEMARKS</u></p> <p>Transmitted herewith is:</p> <ul style="list-style-type: none"> <input checked="" type="checkbox"/> Transmittal of Supplemental Information Disclosure Statement (Under 37 CFR 1.97(b) or 1.97(c)) <input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> 2 Cited References <input checked="" type="checkbox"/> Postcard <div style="margin-top: 50px;">  7/12/04 </div> <div style="margin-top: 20px;"> <p>H. Frederick Rusche, Reg. No. 45,061 Husch & Eppenberger, LLC 190 Carondelet Plaza St. Louis, MO 63105 314-480-1500 314-480-1505 FAX</p> </div> <div style="margin-top: 20px;"> <p>Customer No. 029493</p> </div>						
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="padding: 5px;"> I certify that the document and fee is being deposited on <u>7-12-04</u> with the U.S. Postal Service as Express Mail under 37 C.F.R. 1.10 and is addressed to the Mail Stop Patent Applications, P.O. Box 1450, Commissioner for Patents, Box Provisional Patent Application, Alexandria, VA 22313-1450. </td> </tr> <tr> <td style="padding: 5px;"> Express Mail No.: EV332072599US  Signature of Person Mailing Correspondence </td> </tr> <tr> <td style="padding: 5px; text-align: center;"> Lisa Schodrowski Typed or Printed Name of Person Mailing Correspondence </td> </tr> </table>				I certify that the document and fee is being deposited on <u>7-12-04</u> with the U.S. Postal Service as Express Mail under 37 C.F.R. 1.10 and is addressed to the Mail Stop Patent Applications, P.O. Box 1450, Commissioner for Patents, Box Provisional Patent Application, Alexandria, VA 22313-1450.	Express Mail No.: EV332072599US  Signature of Person Mailing Correspondence	Lisa Schodrowski Typed or Printed Name of Person Mailing Correspondence
I certify that the document and fee is being deposited on <u>7-12-04</u> with the U.S. Postal Service as Express Mail under 37 C.F.R. 1.10 and is addressed to the Mail Stop Patent Applications, P.O. Box 1450, Commissioner for Patents, Box Provisional Patent Application, Alexandria, VA 22313-1450.						
Express Mail No.: EV332072599US  Signature of Person Mailing Correspondence						
Lisa Schodrowski Typed or Printed Name of Person Mailing Correspondence						

P16B/REV01

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 57294-019	
In Re Application Of: Roger K. Cady				
Serial No. 10/808,008	Filing Date 03/24/2004	Examiner TBA	Group Art Unit 1614	
Title: Method and Article for Treatment of Sensory Neuron Related Disorders Through Transdermal Application of Botulinum Toxin				
Address to: MAIL STOP Commissioner for Patents P.O. Box 1450 Alexandria, VA 22131-1450				
37 CFR 1.97(b)				
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.				
37 CFR 1.97(c)				
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:				
<div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e); </div>				
OR				
<div style="margin-left: 40px;"> <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p). </div>				



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
Information Disclosure Statement - PTO 1449 (Modified)

PTO/A-820 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Sheet 1 of 1

37 CFR 1.501 INFORMATION DISCLOSURE CITATION IN A PATENT (use as many sheets as necessary)	Docket Number (Optional) 57294-021	Application Number 10/808,008
	Applicant Roger K. Cady	
	Filing Date 03/24/2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial	Ref.	Document Number								Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	6	2	8	0	7	6	3		08/28/2001	Midha et al	424	448	05/10/1999
	AB	6	3	1	2	7	1	6		11/06/2001	Midha et al	424	448	05/02/2000

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref.	Document Number	Issue Date	Country	International Class	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initial	REF.	DOCUMENT
	CA	DUGGAN ET AL., "INHIBITION OF RELEASE OF NEUROTRANSMITTERS FROM RAT DORSAL ROOT GANGLIA BY A NOVEL CONJUGATE OF A CLOSTRIDIUM BOTULINUM TOXIN A ENDOPEPTIDASE FRAGMENT AND ERYTHRINA CRISTAGALLI LECTIN", THE JOURNAL OF BIOLOGICAL CHEMISTRY, VOL 227, NO. 38, SEPT. 20, 2002, PP 34846 - 34852
	CB	BOTOX (BOTULINUM TOXIN TYPE A) PURIFIED NEUROTOXIN COMPLEX (PRODUCT INFORMATION)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.